Roivant Sciences Ltd. (NASDAQ:ROIV) Stock Position Decreased by New York State Teachers Retirement System

New York State Teachers Retirement System decreased its position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 12.8% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 221,721 shares of the company's stock after selling 32,499 shares during the quarter. New York State Teachers Retirement System's holdings in Roivant Sciences were worth $2,237,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in ROIV. Parallel Advisors LLC grew its position in Roivant Sciences by 80.5% in the first quarter. Parallel Advisors LLC now owns 2,485 shares of the company's stock worth $25,000 after acquiring an additional 1,108 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Roivant Sciences by 478.6% in the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock valued at $28,000 after purchasing an additional 1,948 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new stake in Roivant Sciences in the fourth quarter worth $39,000. UMB Bank n.a. boosted its holdings in Roivant Sciences by 112.7% in the first quarter. UMB Bank n.a. now owns 4,143 shares of the company's stock worth $42,000 after purchasing an additional 2,195 shares in the last quarter. Finally, Fifth Third Bancorp increased its position in Roivant Sciences by 59.3% during the first quarter. Fifth Third Bancorp now owns 5,118 shares of the company's stock worth $52,000 after buying an additional 1,905 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.

Insider Activity

In other news, major shareholder Vivek Ramaswamy sold 577,007 shares of the business's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $11.46, for a total transaction of $6,612,500.22. Following the sale, the insider directly owned 37,284,108 shares in the company, valued at approximately $427,275,877.68. The trade was a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Eric Venker sold 100,000 shares of the stock in a transaction on Friday, June 20th. The shares were sold at an average price of $11.45, for a total transaction of $1,145,000.00. Following the completion of the transaction, the chief operating officer owned 1,462,223 shares of the company's stock, valued at approximately $16,742,453.35. This represents a 6.40% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,464,462 shares of company stock worth $39,098,856. 7.90% of the stock is currently owned by company insiders.

Roivant Sciences Stock Up 1.1%

NASDAQ:ROIV opened at $10.86 on Wednesday. The company's 50 day moving average is $11.13 and its 200-day moving average is $10.87. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $13.06. The firm has a market cap of $7.38 billion, a price-to-earnings ratio of -43.44 and a beta of 1.15.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its earnings results on Thursday, May 29th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.15). The firm had revenue of $7.57 million during the quarter, compared to the consensus estimate of $62.17 million. Roivant Sciences had a negative return on equity of 14.76% and a negative net margin of 225.71%. During the same quarter last year, the business earned ($0.23) EPS. Research analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price target on shares of Roivant Sciences in a research report on Wednesday, June 18th.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.